



## Food and Drug Administration Advisory Committee Member Acknowledgment of Financial Interests

Name of Advisory Committee Member: Lindsey Baden, MD

Committee: Antimicrobial Drugs Advisory Committee

Meeting Date: June 8, 2023

I acknowledge that contingent upon public disclosure of the following financial interest related to the agenda item described below. I may be considered for participation in the advisory committee meeting described above

The committee will discuss biologics license application (BLA) 761328, for nirsevimab, a long-acting respiratory syncytial virus (RSV) F protein inhibitor monoclonal antibody for intramuscular use, submitted by AstraZeneca AB. The proposed indication is prevention of RSV lower respiratory tract disease in neonates and infants born during or entering their first RSV season, and children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season.

<u>Type of Interest</u>	<u>Nature</u>	<u>Magnitude</u>
<b>I. Personal/Immediate Family</b>		
None		
<b>II. Other Imputed Interests</b>		
Employment	Harvard University, a competing entity, licenses patents used for competing product	Dr. Baden is not aware of the amount provided to Harvard University.

I hereby request that FDA make this information publicly available on my behalf if the agency grants a waiver allowing me to participate in the meeting described above. I understand that without public disclosure of these interests, I will not participate in the advisory committee meeting described above.

\_\_\_\_\_/S/  
Signature

\_\_\_\_\_  
5/14/23  
Date